Drug Profile
Research programme: enzyme replacement therapeutics - BioStrategies
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator BioStrategies LC
- Class Enzymes
- Mechanism of Action Enzyme replacements; Heparan sulfate sulfatase replacements; Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gaucher's disease; Mucopolysaccharidosis I; Mucopolysaccharidosis III
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Gaucher's-disease in USA (IV)
- 28 Nov 2020 No recent reports of development identified for research development in Gaucher's-disease in USA (Transmucosal)
- 28 Nov 2020 No recent reports of development identified for research development in Mucopolysaccharidosis-I in USA (IV)